Maria Marvich

Array ( [id] => 11047824 [patent_doc_number] => 20160244783 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-08-25 [patent_title] => 'SIMIAN SUBFAMILY E ADENOVIRUSES SAdV-39, -25.2, -26, -30, -37, AND -38 AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/154368 [patent_app_country] => US [patent_app_date] => 2016-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22434 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15154368 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17059014 [patent_doc_number] => 11103596 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-31 [patent_title] => Fabry disease gene therapy [patent_app_type] => utility [patent_app_number] => 15/573203 [patent_app_country] => US [patent_app_date] => 2016-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 11 [patent_no_of_words] => 8426 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15573203 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16028629 [patent_doc_number] => 10676723 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-09 [patent_title] => Chimeric protein toxins for expression by therapeutic bacteria [patent_app_type] => utility [patent_app_number] => 15/151194 [patent_app_country] => US [patent_app_date] => 2016-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 38 [patent_no_of_words] => 17626 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 128 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15151194 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12702619 [patent_doc_number] => 20180126039 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-10 [patent_title] => COMPOSITIONS COMPRISING MESENCHYMAL STEM CELLS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/571460 [patent_app_country] => US [patent_app_date] => 2016-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19344 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15571460 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12751279 [patent_doc_number] => 20180142260 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-24 [patent_title] => PROMOTERS FOR EXPRESSION OF HETEROLOGOUS GENES [patent_app_type] => utility [patent_app_number] => 15/572101 [patent_app_country] => US [patent_app_date] => 2016-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16632 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -51 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15572101 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16815760 [patent_doc_number] => 11000560 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-05-11 [patent_title] => Oncolytic adenoviruses with mutations in immunodominant adenovirus epitopes and their use in cancer treatment [patent_app_type] => utility [patent_app_number] => 15/571698 [patent_app_country] => US [patent_app_date] => 2016-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 27415 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15571698 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12562704 [patent_doc_number] => 10016470 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-07-10 [patent_title] => Oncolytic adenoviruses for cancer treatment [patent_app_type] => utility [patent_app_number] => 15/144637 [patent_app_country] => US [patent_app_date] => 2016-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 12505 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15144637 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12624942 [patent_doc_number] => 20180100144 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-12 [patent_title] => COMPOSITIONS AND METHODS FOR THE TREATMENT OF NUCLEOTIDE REPEAT EXPANSION DISORDERS [patent_app_type] => utility [patent_app_number] => 15/569203 [patent_app_country] => US [patent_app_date] => 2016-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8995 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15569203 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12641226 [patent_doc_number] => 20180105573 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-19 [patent_title] => NUCLEIC ACID CONSTRUCT FOR EXPRESSING MORE THAN ONE CHIMERIC ANTIGEN RECEPTOR [patent_app_type] => utility [patent_app_number] => 15/568868 [patent_app_country] => US [patent_app_date] => 2016-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17962 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15568868 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12660481 [patent_doc_number] => 20180111993 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-26 [patent_title] => NUCLEIC ACID CONSTRUCT FOR EXPRESSING MORE THAN ONE CHIMERIC ANTIGEN RECEPTOR [patent_app_type] => utility [patent_app_number] => 15/568881 [patent_app_country] => US [patent_app_date] => 2016-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20911 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15568881 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12637473 [patent_doc_number] => 20180104321 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-19 [patent_title] => NUCLEIC ACID CONSTRUCT FOR EXPRESSING MORE THAN ONE CHIMERIC ANTIGEN RECEPTOR [patent_app_type] => utility [patent_app_number] => 15/568874 [patent_app_country] => US [patent_app_date] => 2016-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20801 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15568874 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11568893 [patent_doc_number] => 20170107537 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-20 [patent_title] => 'IDENTIFICATION OF MUTATIONS IN HERPES SIMPLEX VIRUS ENVELOPE GLYCOPROTEINS THAT ENABLE OR ENHANCE VECTOR RETARGETING TO NOVEL NON-HSV RECEPTORS' [patent_app_type] => utility [patent_app_number] => 15/137953 [patent_app_country] => US [patent_app_date] => 2016-04-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 16740 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15137953 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12347595 [patent_doc_number] => 09951368 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-04-24 [patent_title] => Methods of DNA constructs for high yield production of polypeptides [patent_app_type] => utility [patent_app_number] => 15/137134 [patent_app_country] => US [patent_app_date] => 2016-04-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 21 [patent_no_of_words] => 23825 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 142 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15137134 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11047822 [patent_doc_number] => 20160244781 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-08-25 [patent_title] => 'HYBRID CAULIMOVIRUS PROMOTERS AND CONSTRUCTS THEREOF' [patent_app_type] => utility [patent_app_number] => 15/136726 [patent_app_country] => US [patent_app_date] => 2016-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 23302 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15136726 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11107901 [patent_doc_number] => 20160304872 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-20 [patent_title] => 'FRACTIONAL REGULATION OF TRANSCRIPTION' [patent_app_type] => utility [patent_app_number] => 15/132190 [patent_app_country] => US [patent_app_date] => 2016-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 48 [patent_figures_cnt] => 48 [patent_no_of_words] => 12876 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15132190 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16184686 [patent_doc_number] => 10717993 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-07-21 [patent_title] => Methods and compositions for increased transgene expression [patent_app_type] => utility [patent_app_number] => 15/095858 [patent_app_country] => US [patent_app_date] => 2016-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 14 [patent_no_of_words] => 13896 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15095858 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11023745 [patent_doc_number] => 20160220700 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-08-04 [patent_title] => 'METHOD TO KILL PATHOGENIC MICROBES IN A PATIENT' [patent_app_type] => utility [patent_app_number] => 15/096214 [patent_app_country] => US [patent_app_date] => 2016-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 7331 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15096214 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16634317 [patent_doc_number] => 10912804 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-09 [patent_title] => Compositions and methods for treating diseases [patent_app_type] => utility [patent_app_number] => 15/088167 [patent_app_country] => US [patent_app_date] => 2016-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 52 [patent_figures_cnt] => 104 [patent_no_of_words] => 24579 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15088167 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11076039 [patent_doc_number] => 20160273003 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-22 [patent_title] => 'USE OF MEGANUCELASES FOR INDUCING HOMOLOGOUS RECOMBINATION EX VIVO AND IN TOTO IN VERTEBRATE SOMATIC TISSUES AND APPLICATION THEREOF' [patent_app_type] => utility [patent_app_number] => 15/080232 [patent_app_country] => US [patent_app_date] => 2016-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 30255 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15080232 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16695525 [patent_doc_number] => 10946094 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-16 [patent_title] => Adenoassociated viral mediated persistant anti-VEGF therapy for ovarian cancer [patent_app_type] => utility [patent_app_number] => 15/052697 [patent_app_country] => US [patent_app_date] => 2016-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 7886 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15052697 [rel_patent_id] =>[rel_patent_doc_number] =>)